IP Library Granted Patent US 9,481,720
Granted Patent B2
US 9,481,720 · App. 12/733,005 · Granted Nov 1, 2016

BNP(1-32) epitope and antibodies directed against said epitope

Inventors: Francois Rieunier (Bois d'Arcy, FR); Isabelle Giuliani (Garches, FR); Sylvie Villard-Saussine (Issy les Moulineaux, FR)
Assignee: BIO-RAD INNOVATIONS
C07K14/58G01N33/74G01N2333/58G01N2800/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,481,720
App. No.
12/733,005
Granted
Nov 1, 2016
Kind
B2
Abstract

The present invention relates to a polypeptide carrying a human BNP(I-32) epitope according to Formula (I): a 1 -R 1 -X 1 -FGRKMDR-X 2 -R 2 -a 2 as well as ligands specific of the FGRKMDR epitope.

Claims (40)

1. A method for preparing antibodies directed against human BNP(1-32) or human proBNP(1-108) as well as fragments of human BNP(132) or of human proBNP(1-108) comprising sequence FGRKMDR (SEQ ID NO: 51), comprising the steps of

injecting an animal with a polypeptide coupled to an immunogenic carrier protein, wherein the polypeptide is selected from the group consisting of a 1 -SGCFGRKMDR-a 2 (SEQ ID NO: 33), a 1 -GCFGRKMDRI-a 2 , (SEQ ID NO: 34), a 1 -CFGRKMDRIS-a 2 (SEQ ID NO: 35), a 1 -FGRKMDRISS-a 2 (SEQ ID NO: 36), and a 1 -FGRKMDR-a 2 (SEQ ID NO: 51), wherein a 1 is H, a thiol group, alcohol group, aminoxy group, primary amine or secondary amine functional group, an amino carboxyl group, a biotinyl group, or an acetyl group, and wherein a 2 is OH, an NH 2 functional group, or an alcoxyl group, and

recovering from the animal produced antibodies directed against human BNP(1-32) or human proBNP(1-108) as well as fragments of human BNP(1-32) or of human proBNP(1-108) comprising the sequence FGRKMDR (SEQ ID NO: 51).

2. A hybridoma deposited on Apr. 13, 2007 at the CNCM (Collection Nationale de Cultures de Microorganismes, Institut Pasteur, 25, rue du Docteur Roux, 75 724 Paris Cedex 15, France) under registration number CNCM I-3746.

3. A ligand specifically recognizing an epitope consisting of the sequence FGRKMDR (SEQ ID NO: 51) and not interacting substantially with any of the peptide sequences VQGSGCFGR (SEQ ID NO; 21), SPKMVQGSGC (SEQ ID NO: 22), MDRISSSSGLG (SEQ ID NO: 23), RKMDRI (SEQ ID NO: 24), and RKMDRISS (SEQ ID NO: 25), wherein said ligand is selected from the group consisting of an antibody and a fragment of said antibody which specifically recognizes the epitope, each of the antibody and the fragment of said antibody containing all the Complementary Determining Regions (CDR) of, as arranged in, the monoclonal antibody produced by the hybridoma deposited on Apr. 13, 2007 at the CNCM (Collection Nationale de Cultures de Microorganismes, Institut Pasteur, 25, rue du Docteur Roux, 75 724 Paris Cedex 15, France) under registration number CNCM I-3746.

4. A method for detecting, in a biological sample, human BNP(1-32) or a derivative of human proBNP(1-108) containing sequence FGRKMDR (SEQ ID NO: 51), comprising the steps of

1) contacting the biological sample with at least one ligand specifically recognizing an epitope consisting of the sequence FGRKMDR (SEQ ID NO: 51) and not interacting substantially with any of the peptide sequences VQGSGCFGR (SEQ ID NO: 21), SPKMVQGDGC (SEQ ID NO: 22), MDRISSSSGLG (SEQ ID NO: 23), RKMDRI (SEQ ID NO: 24), and RKMDRISS (SEQ ID NO: 25), wherein said ligand is selected from the group consisting of an antibody and a fragment of said antibody which specifically recognizes the epitope, under conditions allowing antigen-ligand complexes to form, each of the antibody and the fragment of said antibody containing all the Complementary Determining Regions (CDR) of, as arranged in, the monoclonal antibody produced by the hybridoma deposited on Apr. 13, 2007 at the CNCM (Collection Nationale de Cultures de Microorganismes, Institut Pasteur, 25, rue du Docteur Roux, 75 724 Paris Cedex 15, France) under registration Number CNCM I-3746 and

2) detecting any said complexes which may have formed.

5. A multiepitopic calibrator having the following general formula (III):

t 1 -E 1 -L 1 -E 2 [-L k-1 -E k ] n - t 2   (III)

wherein:

n is an integer between 0 and 8;

k is an integer between 3 and n+2 When n>0;

E 1 , E 2 , and E k are different from one another, one representing the peptide sequence FGRKMDR (SEQ ID NO: 51) except that when n is 0, one of E 1 and E 2 represents the peptide sequence FGRKMDR (SEQ. ID NO: 51),

and the others representing a sequence of 3 to 1.5 amino acids comprised in the sequence of human proBNP (1-108);

t 1 represents a hydrogen atom, an acetyl group, a peptide sequence of 1 to 10 amino acids, a peptide sequence of 1 to 10 N-α acetylated amino acids, a biotinyl or biocytinyl group, a peptide sequence of 1 to 10 amino acids carrying a biotinyl or biocytinyl radical, or a linear amino alkyl (C 1 -C 10 ) carbonyl chain;

t 2 represents a hydroxyl radical, an amino radical, a peptide sequence of 1 to 10 amino acids, a peptide sequence of 1 to 10 amino acids carrying a terminal amino group, or a linear or branched amino alkyl (C 1 -C 10 ) carbonyl chain; and

L 1 and L k represent —NH—(CH 2 ) 5 —CO—.

6. The multiepitopic calibrator according to claim 5 comprising the following general formula (V):

t 1 -E 1 -E 2 - t 2   (V).

7. The multiepitopic calibrator according to claim 5 , selected from the group consisting of the multiepitopic calibrators defined by the following formulae:

Ac-YTLRAPRSPKMVQG-L 1 -FGRKMDR-NH 2 (SEQ ID NO: 56 and SEQ ID NO: 51);

Ac-FGRKMDR-L 1 -SGLGC*KVLRRH-OH(SEQ ID NO: 51 and SEQ ID NO: 68);

Ac-FGRKMDR-L 1 -SGLGC*KVLR-NH 2 (SEQ ID NO: 51 and SEQ ID NO: 69);

Ac-SPKMVQGSG-L 1 -FGRKMDR-NH 2 (SEQ ID NO: 59 and SEQ ID NO: 51);

Ac-YTLRAPRSPKMV-L 1 -FGRKMDR-L 2 -SGLGC*KVLRRH-OH(SEQ ID NO: 66 and SEQ ID NO: 51 and SEQ ID NO: 68); and

Ac-YTLRAPRSPKMV-L 1 -FGRKMDR-L 2 -SGLGC*KVLR-NH(SEQ ID NO: 66 and SEQ ID NO: 51 and SEQ ID NO: 69);

wherein Ac represents an acetyl group and C* represents an acetamidomethyl-blocked cysteine.

8. A kit for detecting human BNP(1-32) or human proBNP(1-108) as well as fragments of human BNP(1-32) or of human proBNP(1-108) comprising sequence FGRKMDR (SEQ ID NO: 51), comprising

(a) a ligand specifically recognizing an epitope consisting of the sequence FGRKMDR (SEQ ID NO: 51) and not interacting substantially with any of the peptide sequences VQGSGCFGR (SEQ ID NO:21), SPKMVQGSGC (SEQ ID NO: 22), MDRISSSSGLG (SEQ ID NO: 23), RKMDRI (SEQ ID NO: 24), and RKMDRISS (SEQ ID NO:25), wherein said ligand is selected from the group consisting of an antibody and a fragment of said antibody which specifically recognizes the epitope, each of the antibody and the fragment of said antibody containing all the Complementary Determining Regions (CDR) of, as arranged in, the monoclonal antibody produced by the hybridoma deposited on Apr. 13, 2007 as the CNCM (Collection Nationale de Cultures do Microorganismes, Institut Pasteur, 25, rue du Docteur Roux, 75 724 Paris Cedex 15, France) under registration number CNCM I-3746, and

(b) a multiepitopic calibrator having the following general formula (III):

t 1 -E 1 -E 2 [-L k-1 -E k ] n - t 2   (III)

wherein:

n is an integer between 0 and 8;

k is an integer between 3 and n+2 when n>0;

E 1 , E 2 , and E k are different from one another, one representing the peptide sequence FGRKMDR (SEQ ID NO: 51) except that when n is 0, one of E 1 and E 2 represents the peptide sequence FGRKMDR (SEQ ID NO: 51),

and the others representing a sequence of 3 to 15 amino acids comprised in the sequence of human proBNP(1-108);

t 1 represents a hydrogen atom, an acetyl group, a peptide sequence of 1 to 10 amino acids, a peptide sequence of 1 to 10 N-α acetylated amino acids, a biotinyl or biocytinyl group, a peptide sequence of 1 to 10 amino acids carrying a biotinyl or biocytinyl radical, or a linear amino alkyl (C 1 -C 10 ) carbonyl chain;

t 2 represents a hydroxyl, radical, an amino radical, a peptide sequence of 1 to 10 amino acids, a peptide sequence of 1 to 10 amino acids carrying a terminal amino group, or a linear or branched amino alkyl (C 1 -C 10 ) carbonyl chain; and

L 1 and L k represent —NH—(CH 2 ) 5 —CO—.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 8, 2019
From: BIO-RAD INNOVATIONS
To: BIO-RAD EUROPE GMBH
Reel/Frame 049122/0754 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 16, 2018
From: BIO-RAD INNOVATIONS
To: BIO-RAD EUROPE GMBH
Reel/Frame 047588/0504 →
CORRECTIVE ASSIGNMENT TO ADD OMITTED SECOND RECEIVING PARTY PREVIOUSLY RECORDED ON REEL 024149 FRAME 0394. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Nov 3, 2016
From: RIEUNIER, FRANCOIS; GIULIANI, ISABELLE; VILLARD-SAUSSINE, SYLVIE
To: BIO-RAD PASTEUR; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)
Reel/Frame 040552/0272 →
CHANGE OF NAME Recorded Jan 9, 2012
From: BIO-RAD PASTEUR
To: BIO-RAD INNOVATIONS
Reel/Frame 027498/0270 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2010
From: RIEUNIER, FRANCOIS; GIULIANI, ISABELLE; VILLARD-SAUSSINE, SYLVIE
To: BIO-RAD PASTEUR
Reel/Frame 024149/0394 →
Priority Claims (1)
FR 07 05711 · Aug 3, 2007 · national
Continuity (1)
Related Publication 20100209939A1 · Aug 19, 2010